Kohl probes device DTC, threatens ad ban push

Share this article:
Kohl probes device DTC, threatens ad ban push
Kohl probes device DTC, threatens ad ban push
Sen. Herb Kohl said he was “prepared to call for future moratoriums” on DTC for new medical devices, citing “real risks and serious complications.”

Kohl (D-WI), who chairs the Senate Special Committee on Aging, said “Physicians and consumers must be appropriately educated about these critical devices and their benefits and risks alike, What we do in the near term will be dependent on the proactive actions of FDA and industry.”

His comments followed committee hearings into DTC for medical devices in which physicians argued that device DTC undermines the doctor-patient relationship and can raise healthcare costs. Upbeat ads for the Cypher stent, from J&J's Cordis, came in for special criticism. Cordis' “Life wide open” TV campaign debuted last Thanksgiving but has since been restricted to a single market outside Baltimore.

The device industry's DTC spending remains small by comparison to that for pharmaceuticals – according to TNS Media Intelligence, device makers spent $193 million on advertising last year – but it's growing fast. In convening the hearings, Kohl said the device industry was “beginning to get into the game,” and that it was time the FDA began subjecting it to the same scrutiny as it does pharmaceutical manufacturers.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in News

New lipid agents are high on potency, low on doc awareness

New lipid agents are high on potency, low ...

The new PCSK9 class of cholesterol-lowering antibodies continues to look promising, but many doctors—particularly PCPs—have never even heard of the experimental drugs.

Novartis may have game-changing drug

Novartis may have game-changing drug

Key opinion leaders indicate they are ready to embrace Novartis's experimental heart failure medication LCZ696. Such a move could upend heart failure treatment protocols.

Five things for pharma marketers to know: Tuesday, September 2

Five things for pharma marketers to know: Tuesday, ...

Sanofi and Regeneron unveil Phase-III results of their PCSK9; Merck will present data on its anti-PD-1 at the end of this month; WSJ op/ed suggests US should lead fight against ...